EASL Roundup: Bristol-Myers and NGM post a positive look at PhII NASH data; Genfit details PhIII delay
Over the weekend some of the prospective players in the NASH field had a chance to roll out new data on their contenders for the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
